The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Artemisinin-based combination therapy for treating uncomplicated malaria
Open accessAbstract
BACKGROUND: The World Health Organization recommends uncomplicated P. falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT). This review aims to assist the decision making of malaria control programmes by providing an overview of the relative benefits and harms of the available options. OBJECTIVES: To compare the effects of ACTs with other available ACT and non-ACT combinations for treating uncomplicated P. falciparum malaria. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; LILACS, and the metaRegister of Controlled Trials (mRCT) to March 2009. SELECTION CRITERIA: Randomized head to head trials of ACTs in uncomplicated P. falciparum malaria.This review is limited to: dihydroartemisinin-piperaquine; artesunate plus mefloquine; artemether-lumefantrine (six doses); artesunate plus amodiaquine; artesunate plus sulfadoxine-pyrimethamine and amodiaquine plus sulfadoxine-pyrimethamine. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials for eligibility and risk of bias, and extracted data. We analysed primary outcomes in line with the WHO 'Protocol for assessing and monitoring antimalarial drug efficacy' and compared drugs using risk ratios (RR) and 95% confidence intervals (CI). Secondary outcomes were effects on P. vivax, gametocytes, haemoglobin, and adverse events. MAIN RESULTS: Fifty studies met the inclusion criteria. All five ACTs achieved PCR adjusted failure rates of < 10%, in line with WHO recommendations, at most study sites.Dihydroartemisinin-piperaquine performed well compared to the ACTs in current use (PCR adjusted treatment failure versus artesunate plus mefloquine in Asia; RR 0.39, 95% CI 0.19 to 0.79; three trials, 1062 participants; versus artemether-lumefantrine in Africa; RR 0.39, 95% CI 0.24 to 0.64; three trials, 1136 participants).ACTs were superior to amodiaquine plus sulfadoxine-pyrimethamine in East Africa (PCR adjusted treatment failure versus artemether-lumefantrine; RR 0.12, 95% CI 0.06 to 0.24; two trials, 618 participants; versus AS+AQ; RR 0.44, 95% CI 0.22 to 0.89; three trials, 1515 participants).Dihydroartemisinin-piperaquine (RR 0.32, 95% CI 0.24 to 0.43; four trials, 1442 participants) and artesunate plus mefloquine (RR 0.30, 95% CI 0.21 to 0.41; four trials, 1003 participants) were more effective than artemether-lumefantrine at reducing the incidence of P.vivax over 42 days follow up. AUTHORS' CONCLUSIONS: Dihydroartemisinin-piperaquine is another effective first-line treatment for P. falciparum malaria.The performance of the non-ACT (amodiaquine plus sulfadoxine-pyrimethamine) falls below WHO recommendations for first-line therapy in parts of Africa.In areas where primaquine is not being used for radical cure of P. vivax, ACTs with long half-lives may provide some benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy
Meshnick, S. R., Taylor, T. E., & Kamchonwongpaisan, S. (1996) · Microbiological Reviews · doi:10.1128/mmbr.60.2.301-315.1996 · Cited by 710
Cited by
Global health 2035: a world converging within a generation
Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A., Bustreo, F., Evans, D., Feachem, R. G. A., Frenk, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62105-4 · Cited by 1,220
Bousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Boeker, M., Vach, W., & Motschall, E. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-131 · Cited by 225
“We retrieved the newest versions of the 14 Cochrane reviews from the Database of Systematic Reviews Issue 3/2013 used in [9] from the Cochrane Library [21-34 , Where available, the documented search strategies for MEDLINE (OvidSP or PubMed) searches were extracted from the Cochrane reviews.”
BackgroundMethodTerpenoid biosynthesis in trichomes—current status and future opportunities
Markus Lange, B., & Turner, G. W. (2013) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2012.00737.x · Cited by 195
Barrington, J., Wereko-Brobby, O., Ward, P., Mwafongo, W., & Kungulwe, S. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-298 · Cited by 163
Metadata
- Authors
- Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-07-08
- Volume
- 2019
- Issue
- 5
- Pages
- CD007483-CD007483
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1825014948
- Cited by
- 286
- References
- 2
- FWCI
- 29.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Artemisinin-based combination therapy for treating uncomplicated malaria. https://app.cochat.ai/papers/10.1002/14651858.cd007483.pub2
- The paper
- Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009). Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd007483.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.